Blog
RSS FeedPosted by Michael Wonder on 28 Jul 2021
Advisory panel to develop a framework for a pan-Canadian prescription drug list
27 July 2021 - An Advisory Panel has been convened by CADTH to provide Health Canada with a recommended framework ...
Posted by Michael Wonder on 22 Jul 2021
Dupixent (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
22 July 2021 - Recommendation supported by multiple clinical trials that demonstrated a reduced frequency of asthma exacerbations compared to placebo, ...
Posted by Michael Wonder on 15 Jul 2021
Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug
15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief ...
Posted by Michael Wonder on 13 Jul 2021
'A price on your life': Toronto cystic fibrosis patients slam review process while waiting for access to life-saving treatment
13 July 2021 - While Health Canada approved Trikafta for patient use on June 18, 2021, it is still not ...
Posted by Michael Wonder on 30 Jun 2021
Canada again delays overhaul to patented medicine pricing system
29 June 2021 - Health Minister Patty Hajdu is delaying the first big overhaul of Canada’s patented medicines pricing system ...
Posted by Michael Wonder on 24 Jun 2021
PMPRB risks harming the health of Canadians by reducing access to new medicines
23 June 2021 - On June 21, Innovative Medicines Canada submitted six recommendations to the federal government as part of the ...
Posted by Michael Wonder on 23 Jun 2021
Rare disease patient advocates continue battle for affordable drugs
23 June 2021 - Beth Vanstone, mother of local Cystic Fibrosis Warrior Madi Vanstone and director of the CF Get ...
Posted by Michael Wonder on 18 Jun 2021
Let's have permanently quicker drug approvals
16 June 2021 - New drugs and vaccines likely to increase life expectancy, quality of life and save money, so we ...
Posted by Michael Wonder on 05 Jun 2021
Put Canadians first by suspending the implementation of harmful drug pricing regulations
4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...
Posted by Michael Wonder on 03 Jun 2021
Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents
1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...
Posted by Michael Wonder on 31 May 2021
Campaign launched for life-sustaining treatment access across Canada
31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 ...
Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...
Posted by Michael Wonder on 18 May 2021
Quebec announces intention to implement a biosimilar switching policy
18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...
Posted by Michael Wonder on 18 May 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...
Posted by Michael Wonder on 17 May 2021
Sandoz Canada launches its 6th biosimilar with Inclunox and Inclunox HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency))
17 May 2021 - New Sandoz biosimilar launch can potentially lower healthcare costs, especially for Canadian hospitals, as 75% of the ...